CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $1.85B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
12.48BCNY1.85B · vs all stocks (USD)
Revenue (TTM)
385.54MCNY57.18M · vs all stocks (USD)
Profit Margin
-16.94%52-Week Change
21.20%vs all stocks
Market Capitalization
12.48BCNY1.85B · vs all stocks (USD)
Enterprise Value
4.41BCNY653.96M · vs all stocks (USD)
Forward P/E
24.48xPrice to Sales (TTM)
32.40xPrice to Book (MRQ)
2.97xEnterprise to Revenue
11.44xGross Margin
69.24%Profit Margin
-16.94%Operating Margin
6.75%Return on Assets (TTM)
-1.43%Return on Equity (TTM)
-6.28%Revenue (TTM)
385.54MCNY57.18M · vs all stocks (USD)
Revenue per Share (TTM)
0.4410CNYUpdated Aug 18, 2026Quarterly Revenue Growth
7.40%Gross Profit (TTM)
234.76MCNY34.82M · vs all stocks (USD)
EBITDA (TTM)
20.12MCNY2.98M · vs all stocks (USD)
Net Income (TTM)
-65.32MCNY-9.69M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.42%Operating Cash Flow (TTM)
-23.67MCNY-3.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.90MCNY-13.33M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-51.39MCNYFY2025 · Dec 31, 2025Revenue
378.11MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
140.32MCNYFY2025 · Dec 31, 2025Gross Profit
237.79MCNYFY2025 · Dec 31, 2025Operating Income
-27.89MCNY-4.14M · vs all stocks (USD)
Pre-tax Income
-77.60MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.44MCNYFY2025 · Dec 31, 2025Net Income
-79.05MCNYFY2025 · Dec 31, 2025EBIT
-47.23MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
20.12MCNYFY2025 · Dec 31, 2025Research & Development
11.00MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
183.72MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.42MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
417.45KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
30.37MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0919CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0919CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
880.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
880.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-79.05MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.84MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-104.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
-108.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
37.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-79.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
30.86MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-50.94MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.75MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-31.46MCNYFY2025 · Dec 31, 2025Sale of Investments
119.68MCNYFY2025 · Dec 31, 2025Other Investing Activity
426.99KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
84.68MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00CNYFY2025 · Dec 31, 2025Long-term Debt Payments
-143.28MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-10.53MCNYFY2025 · Dec 31, 2025Other Financing Charges
-11.25MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-165.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.76BSharesUpdated Aug 18, 2026Float Shares
521.61MSharesUpdated Aug 18, 2026% Held by Insiders
51.64%vs all stocks
% Held by Institutions
7.60%vs all stocks
Total Cash (MRQ)
1.75BCNY259.74M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.00CNYUpdated Aug 18, 2026Total Debt (MRQ)
7.12MCNY1.06M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0035xCurrent Ratio (MRQ)
4.47xBook Value per Share (MRQ)
2.39CNYUpdated Aug 18, 2026Total Assets
819.95MCNY121.60M · vs all stocks (USD)
Total Current Assets
275.35MCNYFY2025 · Dec 31, 2025Total Liabilities
848.20MCNYFY2025 · Dec 31, 2025Total Non-current Assets
544.60MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
46.64MCNYFY2025 · Dec 31, 2025Total Current Liabilities
801.56MCNYFY2025 · Dec 31, 2025Cash
37.48MCNYFY2025 · Dec 31, 2025Cash Equivalents
38.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
75.60MCNYFY2025 · Dec 31, 2025Accounts Receivable
45.23MCNYFY2025 · Dec 31, 2025Inventory
38.83MCNYFY2025 · Dec 31, 2025Accounts Payable
107.92MCNYFY2025 · Dec 31, 2025Short-term Debt
87.43MCNYFY2025 · Dec 31, 2025Other Current Liabilities
194.81MCNYFY2025 · Dec 31, 2025Long-term Debt
5.88MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
26.35MCNYFY2025 · Dec 31, 2025Common Stock (Book)
416.69MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.13BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
-28.25MCNY-4.19M · vs all stocks (USD)
52-Week Low
4.58CNYUpdated Aug 18, 202652-Week High
9.48CNYUpdated Aug 18, 202652-Week Change
21.20%vs all stocks
50-Day MA
6.43CNYUpdated Aug 18, 2026200-Day MA
7.09CNYUpdated Aug 18, 2026Avg 10-Day Volume
34.57MSharesUpdated Aug 18, 2026Avg 30-Day Volume
37.68MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
-0.0700CNYUpdated Aug 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 32.40Revenue Growth YoY: 0.07
High gross margins eroded by operating costsNotable
Gross Margin: 0.69Profit Margin: -0.17
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $1.85B, above the global median of $1.15BNotable
Market cap (USD): 1,850,072,204.045Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow